Abstract
Throughout the past twenty years numerous tumor markers have been introduced, but for majority of them specific clinical applications have been limited and only a few markers have been approved by health organizations. This study reviews consensus recommendations made by the National Academy of Clinical Biochemistry (NACB) in the United States and the European Group on Tumor Markers (EGTM). The approach of both the NACB and EGTM groups has been similar, each group considering appropriate use of tumor marker for specific types of cancer. The current guidelines developed by the two groups are considered as follows: quality requirements and control, breast cancer, gynecological cancer, prostate cancer, colorectal cancer, neuroendocrine tumors, germ cell tumors, monoclonal gammopathies and lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
